论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Xu YF, Li F, Jia RB, Fan XQ
Received 10 January 2018
Accepted for publication 10 April 2018
Published 27 June 2018 Volume 2018:11 Pages 3713—3720
DOI https://doi.org/10.2147/OTT.S162073
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Jianmin Xu
Abstract: Ocular sebaceous
carcinoma (SC) is an exceedingly rare but aggressive malignancy that can impair
patients’ visual acuity or even cause tumor-specific mortality. This tumor
usually mimics chronic benign eyelid lesions, thus leading to delayed
diagnosis, thereby causing high recurrence and metastasis. Ophthalmologists
should be more aware of SC in order to offer correct diagnosis and treatment at
the onset of symptoms. Prompt surgical excision with frozen section margin
control is the mainstay of SC management after patient evaluation and accurate
biopsy. Mohs micrographic surgery has been associated with better tumor control
outcomes than wide local excision. Radiation therapy should be considered as
adjuvant treatment for locally advanced (stage T3a or higher) or high-risk
(pagetoid spread) SC, nodal metastasis, or palliative care. Cryotherapy and
topical chemotherapy are used for pagetoid spread. Targeted therapy has an
emerging role in more complicated cases. For lymph node and distant metastasis,
combination treatments should be provided, including lymph node and neck
dissection, radiation therapy, systemic chemotherapy, and even orbital
exenteration. The rarity of ocular SC precludes a comprehensive perspective on
standard treatment. This paper offers a brief review of recent advances in the
clinical diagnosis and management of ocular SC based on current scientific
literature.
Keywords: sebaceous
carcinoma, periocular cancers, therapy, Mohs micrographic surgery